Fundraising FoxAsclepiX Therapeutics, Inc.
Bethesda, US · Founded 2023 · Delaware corporation · 2 known investors
Find your way into AsclepiX Therapeutics, Inc.
Each arrow is one introduction. Sign up to fill in the first one.
Ask Steve Altschuler to introduce you to Jordan J. Green
You →Steve · together at AsclepiX Therapeutics, Inc. →Jordan
Ask Jamie Chen to introduce you to Wendy Perrow
You →Jamie · together at Alba Therapeutics, Inc. →Wendy
Sign up to find every way you can get introduced to AsclepiX Therapeutics, Inc.
- Your email: who you already know at AsclepiX Therapeutics, Inc., and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the AsclepiX Therapeutics, Inc. team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Biopharmaceutical company using computational biology to identify and develop novel peptide therapies, including AXT107 for retinal/eye diseases.
Founders & leadership
AsclepiX Therapeutics, Inc. was founded in 2023 by Aleksander S. Popel, PhD and Jordan J. Green.
Investors · 2
How we know: Rapha Capital Management, LLC's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$28M disclosed across 4 rounds · 2017–2023
▶$10MraisedApr 2024 · 9 investors · BiotechnologyRule 506(b)
- Robert DempseyExecutive Officer
- Steven AltschulerDirector
- Ben AskewDirector
- Josh BarerDirector
- Chris GarabedianDirector
- Aleksander PopelExecutive Officer
- Sapna SrivastavaDirector
- Amir ShojaeiExecutive Officer
- Niranjan PandeyExecutive Officer
- Jill TierneyExecutive Officer
- Jordan GreenDirector
- Offering amount
- $12.5M
- Amount sold
- $10M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$10MraisedJun 2020 · 34 investors · BiotechnologyRule 506(b)
- Sapna SrivastavaDirector
- Aleksander S. Popel, PhDDirector
- Jordan J. GreenDirector
- Kevin Slawin, MDExecutive Officer, Director
- Steven Altschuler, MDDirector
- Joshua BarerDirector
- Offering amount
- $35M
- Amount sold
- $10M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.7MraisedJun 2019 · 26 investors · BiotechnologyRule 506(b)
- Steven Altschuler, MDDirector
- Sapna SrivastavaDirector
- Joshua BarerDirector
- Kevin Slawin, MDDirector
- Aleksander S. Popel, PhDDirector
- Wendy PerrowExecutive Officer, Director
- Jordan J. GreenDirector
- Offering amount
- $10M
- Amount sold
- $7.7M
- Sales commissions
- $40K
- Proceeds to insiders
- $575K
- Placement agents
- Solebury Capital LLC
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$175KraisedFeb 2017 · 5 investors · BiotechnologyRule 506(b)
- Aleksander S. Popel, PhDExecutive Officer, Director
- Jordan J. GreenExecutive Officer, Director
- Wendy PerrowExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $175K
- First sale
- Feb 2017
- Incorporated
- Limited Liability Company, Maryland
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $299.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $278.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $260.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $258K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does AsclepiX Therapeutics, Inc. do?
- Biopharmaceutical company using computational biology to identify and develop novel peptide therapies, including AXT107 for retinal/eye diseases.
- Who founded AsclepiX Therapeutics, Inc.?
- AsclepiX Therapeutics, Inc. was founded by Aleksander S. Popel, PhD, Jordan J. Green in 2023.
- Who are AsclepiX Therapeutics, Inc.'s investors?
- AsclepiX Therapeutics, Inc.'s investors include Rapha Capital Management, LLC, Perceptive Xontogeny Venture.
- How much funding has AsclepiX Therapeutics, Inc. raised?
- AsclepiX Therapeutics, Inc. has disclosed $28M raised across 4 rounds.
- Where is AsclepiX Therapeutics, Inc. headquartered?
- AsclepiX Therapeutics, Inc. is headquartered in Bethesda, US.